Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 24, Issue 23, Pages 2457-2467Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v24.i23.2457
Keywords
Vedolizumab; Crohn's disease; Real-world; Efficacy; Ulcerative colitis; Controlled trial; Effectiveness; Safety
Categories
Ask authors/readers for more resources
The biologic antitumor necrosis factor alpha (anti-TNF alpha) agents have revolutionised the treatment of inflammatory bowel disease (IBD). However, some patients experience primary nonresponse, loss of response, or intolerance. Therefore, introducing a newer class of therapy with a mechanism of action that acts on different inflammatory pathways involved in IBD pathogenesis is appealing. Vedolizumab is a fully humanised monoclonal antibody that selectively targets alpha 4 beta 7 integrin. Based on the results of the pivotal clinical GEMINI trials, vedolizumab was approved for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) refractory or intolerant to either conventional therapy or TNF alpha inhibitors. This review describes the efficacy, safety, and tolerability of vedolizumab reported in both randomized, controlled, clinical trials and from real-world experience in patients with UC and CD in order to identify its place in treatment algorithms for IBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available